Kristine Twomey
Adult Health · Neenah, WINPI 1770728974
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,349 of the $4,581 with a category attached, or 73.1%. 39 manufacturers reported payments, led by Livanova USA, Inc. at 31.7% of the total. Reporting peaked in 2024 at $2,142 and has fallen 58.7% since, to $884 in 2025. Among adult health clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $32.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$1K
- SK Life Science, Inc.$238
- Teva Pharmaceuticals USA, Inc.$232
- UCB, Inc.$225
- Biogen$193
- Otsuka America Pharmaceutical, Inc.$169
- plus $2K from 33 others
What the payments were for
- Travel & lodging$1,13425%
- Food & beverage$3,34973%
- Education$982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 7 | $1,454 |
| SK Life Science, Inc. | 9 | $238 |
| Teva Pharmaceuticals USA, Inc. | 9 | $232 |
| UCB, Inc. | 8 | $225 |
| Biogen | 6 | $193 |
| Otsuka America Pharmaceutical, Inc. | 3 | $169 |
| Biohaven Pharmaceuticals, Inc. | 8 | $162 |
| Novartis | 6 | $154 |
| AbbVie(2 entities) | 6 | $143 |
| Eisai Inc. | 6 | $116 |
| Tanabe Pharma America, Inc. | 6 | $108 |
| Catalyst Pharmaceuticals, Inc. | 4 | $103 |
| Neurocrine Biosciences, Inc. | 6 | $100 |
| Argenx US, Inc. | 4 | $93 |
| Lilly USA, LLC | 5 | $87 |
| Jazz Pharmaceuticals Inc. | 4 | $80 |
| Genentech USA, Inc. | 4 | $77 |
| Pfizer | 4 | $76 |
| Johnson & Johnson(2 entities) | 3 | $67 |
| Amneal Pharmaceuticals LLC | 4 | $63 |
| MDD US Operations, LLC | 3 | $59 |
| Merz Pharmaceuticals, LLC | 3 | $56 |
| Corium, LLC | 2 | $50 |
| Neurelis, Inc. | 2 | $46 |
| Amgen(2 entities) | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Bristol Myers Squibb | 2 | $40 |
| Lundbeck LLC | 2 | $39 |
| Acorda Therapeutics, Inc | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Cala Health, Inc. | 1 | $27 |
| Sanofi | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Avion Pharmaceuticals | 1 | $21 |
| TG Therapeutics, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Hospira, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,380
- REXULTI$124
How this compares
$4,581 in reported general payments places this provider in the 95th percentile of 170 adult health providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 63 | $317,048 |
| RytaryCarbidopa/Levodopa | 97 | $132,359 |
| FycompaPerampanel | 33 | $82,608 |
| RexultiBrexpiprazole | 38 | $64,834 |
| OngentysOpicapone | 37 | $40,500 |
| KeppraLevetiracetam | 16 | $37,680 |
| Rivastigmine | 174 | $35,489 |
| OnfiClobazam | 20 | $34,553 |
| XcopriCenobamate | 27 | $33,305 |
| AptiomEslicarbazepine Acetate | 24 | $32,309 |
| Lamotrigine ErLamotrigine | 120 | $31,308 |
| Lacosamide | 189 | $29,621 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 628 | $29,592 |
| Memantine Hcl | 1,227 | $29,112 |
| Levetiracetam | 671 | $25,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $24 | $317,04863 claims |
| Amneal Pharmaceuticals LLCRytary | $63 | $132,35997 claims |
| Eisai Inc.Fycompa | $116 | $82,60833 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $169 | $64,83438 claims |
| Neurocrine Biosciences, Inc.Ongentys | $100 | $40,50037 claims |
| Lundbeck LLCOnfi | $39 | $34,55320 claims |
| SK Life Science, Inc.Xcopri | $238 | $33,30527 claims |
| UCB, Inc.Vimpat | $225 | $12,86912 claims |
| PfizerDilantin | $76 | $6,44128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 adult health providers in Wisconsin.
Other adult health in Neenah
- Marisa KreuzerNeenah$2K
- Dawn SagrilloWhitefish Bay$247K
- Lindsey SimpsonMuskego$67K
- Winsome PantonMilwaukee$46K
- Anatoliy VelikodanovMilwaukee$10K
- Tatjana StevanovicWest Allis$10K
- Annike CollinsMilwaukee$9K
- Kay ConradtAppleton$4K
- Nicole RosinMilwaukee$4K
- Robert FrankBrandon$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.